Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: Multiple blood markers profiling study

Critical Care

Volumn 17, Issue 2, 2013, Pages

  Park, So Young ^a   Kim, Jinkwon ^a   Kim, Ok Joon ^a   Kim, Jin Kyeoung ^a   Song, Jihwan ^a   Shin, Dong Ah ^b   Oh, Seung Hun ^a  

^a CHA University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; D DIMER; FATTY ACID BINDING PROTEIN; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; HEART TYPE FATTY ACID BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; NEUROGLOBIN; NEURON SPECIFIC ENOLASE; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VISININ; VISININ LIKE PROTEIN 1; BIOLOGICAL MARKER; FABP3 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONG TERM CARE; MACROGLIA; MAJOR CLINICAL STUDY; MALE; NERVE CELL; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; ACUTE DISEASE; BLOOD; CEREBRAL INFARCTION; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CEREBRAL INFARCTION; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874936878     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12564     Document Type: Article

References (39)

1. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004, 61:346-350. 10.1001/archneur.61.3.346, 15023810.
2. Counsell C, Dennis M, McDowall M. Predicting functional outcome in acute stroke: comparison of a simple six variable model with other predictive systems and informal clinical prediction. J Neurol Neurosurg Psychiatry 2004, 75:401-405. 10.1136/jnnp.2003.018085, 1738951, 14966155.
3. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, Welsh P, Green A, Andrews M, Graham C, Sandercock P. Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study. Cerebrovascul Dis 2011, 32:141-147.
4. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, Welsh P, Green A, Andrews M, Sandercock P. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 2012, 43:86-91. 10.1161/STROKEAHA.111.634089, 22020034.
5. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, Wardlaw J, Dennis M, Sudlow C. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009, 6:e1000145. 10.1371/journal.pmed.1000145, 2730573, 19901973.
6. Ehrenreich H, Kastner A, Weissenborn K, Streeter J, Sperling S, Wang KK, Worthmann H, Hayes RL, von Ahsen N, Kastrup A, Jeromin A, Herrmann M. Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med 2011, 17:1306-1310. 3321813, 21912808.
7. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999, 30:1190-1195. 10.1161/01.STR.30.6.1190, 10356098.
8. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont R, Steinmetz H, Sitzer M. Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. Arch Neurol 2005, 62:1130-1134. 10.1001/archneur.62.7.1130, 16009772.
9. Oh SH, Lee JG, Na SJ, Park JH, Choi YC, Kim WJ. Prediction of early clinical severity and extent of neuronal damage in anterior-circulation infarction using the initial serum neuron-specific enolase level. Arch Neurol 2003, 60:37-41. 10.1001/archneur.60.1.37, 12533086.
10. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GD, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009, 27:247-253. 10.1159/000196823, 19176958.
11. Kang DW, Yoo SH, Chun S, Kwon KY, Kwon SU, Koh JY, Kim JS. Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke. Stroke 2009, 40:1653-1658. 10.1161/STROKEAHA.108.539429, 19265045.
12. Whiteley W, Chong WL, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke 2009, 40:e380-389. 10.1161/STROKEAHA.108.528752, 19286602.
13. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC. Clinical usefulness of a biomarker-based diagnostic test for acute stroke: the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 2009, 40:77-85. 10.1161/STROKEAHA.108.516377, 18948614.
14. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41. 10.1161/01.STR.24.1.35, 7678184.
15. Konig IR, Ziegler A, Bluhmki E, Hacke W, Bath PM, Sacco RL, Diener HC, Weimar C. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke 2008, 39:1821-1826. 10.1161/STROKEAHA.107.505867, 18403738.
16. Blanco M, Castellanos M, Rodriguez-Yanez M, Sobrino T, Leira R, Vivancos J, Lizasoain I, Serena J, Davalos A, Castillo J. High blood pressure and inflammation are associated with poor prognosis in lacunar infarctions. Cerebrovasc Dis 2006, 22:123-129. 10.1159/000093240, 16691020.
17. Rodriguez-Yanez M, Castellanos M, Blanco M, Garcia MM, Nombela F, Serena J, Leira R, Lizasoain I, Davalos A, Castillo J. New-onset hypertension and inflammatory response/poor outcome in acute ischemic stroke. Neurology 2006, 67:1973-1978. 10.1212/01.wnl.0000247064.53130.91, 17159103.
18. Shenhar-Tsarfaty S, Ben Assayag E, Bova I, Shopin L, Fried M, Berliner S, Shapira I, Bornstein NM. Interleukin-6 as an early predictor for one-year survival following an ischaemic stroke/transient ischaemic attack. Int J Stroke 2010, 5:16-20. 10.1111/j.1747-4949.2009.00396.x, 20088988.
19. Smith CJ, Emsley HC, Gavin CM, Georgiou RF, Vail A, Barberan EM, del Zoppo GJ, Hallenbeck JM, Rothwell NJ, Hopkins SJ, Tyrrell PJ. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004, 4:2. 10.1186/1471-2377-4-2, 331413, 14725719.
20. Waje-Andreassen U, Krakenes J, Ulvestad E, Thomassen L, Myhr KM, Aarseth J, Vedeler CA. IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005, 111:360-365. 10.1111/j.1600-0404.2005.00416.x, 15876336.
21. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007, 184:53-68. 10.1016/j.jneuroim.2006.11.014, 1868538, 17188755.
22. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001, 115:3-12. 10.1046/j.1365-2141.2001.03061.x, 11722403.
23. Suzuki S, Tanaka K, Nogawa S, Nagata E, Ito D, Dembo T, Fukuuchi Y. Temporal profile and cellular localization of interleukin-6 protein after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1999, 19:1256-1262.
24. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008, 7:489-503. 10.1038/nrd2589, 2821027, 18511927.
25. Liao J, Chan CP, Cheung YC, Lu JH, Luo Y, Cautherley GW, Glatz JF, Renneberg R. Human heart-type fatty acid-binding protein for on-site diagnosis of early acute myocardial infarction. Int J Cardiol 2009, 133:420-423. 10.1016/j.ijcard.2008.01.049, 18571749.
26. Haltern G, Peiniger S, Bufe A, Reiss G, Gulker H, Scheffold T. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol 2010, 105:1-9. 10.1016/j.amjcard.2009.08.645, 20102882.
27. Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, Allard L, Hochstrasser DF, Sanchez JC. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 2004, 3:66-72.
28. Wunderlich MT, Hanhoff T, Goertler M, Spener F, Glatz JF, Wallesch CW, Pelsers MM. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 2005, 252:718-724. 10.1007/s00415-005-0725-z, 15834650.
29. Park SY, Kim MH, Kim OJ, Ahn HJ, Song JY, Jeong JY, Oh SH. Plasma heart-type fatty acid binding protein level in acute ischemic stroke: Comparative analysis with plasma S100B level for diagnosis of stroke and prediction of long-term clinical outcome. Clin Neurol Neurosurg 2013, 115:405-410. 10.1016/j.clineuro.2012.06.004, 22766253.
30. Banki NM, Kopelnik A, Dae MW, Miss J, Tung P, Lawton MT, Drew BJ, Foster E, Smith W, Parmley WW, Zaroff JG. Acute neurocardiogenic injury after subarachnoid hemorrhage. Circulation 2005, 112:3314-3319. 10.1161/CIRCULATIONAHA.105.558239, 16286583.
31. Ishino M, Takeishi Y, Niizeki T, Watanabe T, Nitobe J, Miyamoto T, Miyashita T, Kitahara T, Suzuki S, Sasaki T, Billim O, Kubota I. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3. Circ J 2008, 72:1800-1805. 10.1253/circj.CJ-08-0157, 18832778.
32. Jo YH, Kim K, Lee JH, Rhee JE, Lee JH, Kang KW, Rim KP, Hwang SS, Park HM. Heart-type fatty acid-binding protein as a prognostic factor in patients with severe sepsis and septic shock. Am J Emerg Med 2012, 30:1749-1755. 10.1016/j.ajem.2012.02.005, 22463971.
33. Boscheri A, Wunderlich C, Langer M, Schoen S, Wiedemann B, Stolte D, Elmer G, Barthel P, Strasser RH. Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. Am Heart J 2010, 160:294-300. 10.1016/j.ahj.2010.05.010, 20691835.
34. Akbal E, Ozbek M, Gunes F, Akyurek O, Ureten K, Delibasi T. Serum heart type fatty acid binding protein levels in metabolic syndrome. Endocrine 2009, 36:433-437. 10.1007/s12020-009-9243-6, 19806479.
35. Laterza OF, Modur VR, Crimmins DL, Olander JV, Landt Y, Lee JM, Ladenson JH. Identification of novel brain biomarkers. Clin Chem 2006, 52:1713-1721. 10.1373/clinchem.2006.070912, 16858073.
36. Shang A, Zhou D, Wang L, Gao Y, Fan M, Wang X, Zhou R, Zhang C. Increased neuroglobin levels in the cerebral cortex and serum after ischemia-reperfusion insults. Brain Res 2006, 1078:219-226. 10.1016/j.brainres.2006.01.064, 16492379.
37. Katan M, Fluri F, Schuetz P, Morgenthaler NG, Zweifel C, Bingisser R, Kappos L, Steck A, Engelter ST, Muller B, Christ-Crain M. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol 2010, 56:1045-1053. 10.1016/j.jacc.2010.02.071, 20846604.
38. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Int Med 2006, 166:2073-2080.
39. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, Muller K, Meckel S, Gass A, Kappos L, Steck AJ, Engelter ST, Muller B, Christ-Crain M. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009, 66:799-808. 10.1002/ana.21783, 20035506.